3Gottleb LD, Roer D,Jega K,et al. Clinical pathway for pneu- monia :development,implementation,and initial experience [J]. Best Pract Benchmarking Healthc, 1996,1 (5) : 262. 被引量：1
4Estrada CA, Unterborn JN,Price J,et al. Judging the ef- fectiveness of clinical pathways for pneumonia: the role of risk adjustment [J]. Eft Clin Pract, 2000,3 (5) : 221. 被引量：1
5Dendukuri N,Schiller I,Joseph L,et al. Bayesian meta analysis of the accuracy of a test for tuberculous pleuritis in the absence of a gold standard reference [J]. Biometrics, 2012,22 (5) : 1021-1027. 被引量：1
6Connell TG,Ritz N,Paxton GA,et al. A three-way eom- pafison of tuberculin skin testing,Quanti FERON-TB Gold and T-SPOT TB in children [J]. PLoS One, 2008,3 (7) : 2624. 被引量：1
7Raju B,Tung CF,Cheng D,et al. In situ activation of helper T cells in the lung [J]. Infect-immun,2001,69(8) :4790- 4798. 被引量：1
8Atanackovic D, Block A,de Weerth A,et al. Characterization of effusion-infiltrating T cells: :benign versus malignant effusions [J]. Clin Cancer Res,2004,10 (8) :2600- 2608. 被引量：1
9Diel R, Loddenkempor R, Meywald-Walter K, et al. Comparafiveper formance of tuberculin skin test,quanti FERON-TB-Gold in tube assay,and T-Spot TB test in contact investigations for tuberculosi [J]. Chest,2009,135 (4):1010-1018. 被引量：1
